表紙
市場調査レポート

世界の抗体・薬物複合体(ADC)市場の将来展望

Global Antibody Drug Conjugate Market Outlook 2020

発行 RNCOS E-Services Pvt. Ltd. 商品コード 297685
出版日 ページ情報 英文 80 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
世界の抗体・薬物複合体(ADC)市場の将来展望 Global Antibody Drug Conjugate Market Outlook 2020
出版日: 2015年07月01日 ページ情報: 英文 80 Pages
概要

抗体・薬物複合体(ADC)は目新しいものではなく、1990年代から開発が始まっていました。しかし、薬物用ペイロードの仕様や、抗体と薬物との結合の難しさといった問題から、開発活動は一進一退を繰り返してきました。しかし、リンカー技術やペイロードの機能・仕様に関する大幅な技術進歩が達成されたことにより、ADCの開発はこの数年間で飛躍的に前進しました。現在、AdcetrisとKadcylaという2つの製品が上市されています。全世界のADC市場の規模は、2020年には127億米ドルに達すると予想されています。

当レポートでは、全世界の抗体・薬物複合体(以下ADC)市場について分析し、全体的な産業構造や、上市済み製品の市場動向、治験中の主要薬剤の概要と今後の開発見通し、近年の市場・企業動向、主な産業促進・阻害要因、主要企業のプロファイルなどを調査しています。

第1章 アナリストの見解

第2章 分析手法

第3章 抗体・薬物複合体(ADC):概略

第4章 ADC市場の将来展望

  • Adcetris
  • Kadcyla
    • 市場の将来性
    • 市場規模とその予測(今後6年間分)

第5章 パイプライン分析

  • 相別
  • 症状別
  • 薬剤別

第6章 市場の促進要因と課題

  • 促進要因
  • 課題

第7章 パイプライン上の潜在的ADCの現状

  • Glembatumumab Vedotin Therapeutics /CDX-011 - Celldex
  • Coltuximab Ravtansine/SAR3419 - Immunogen Inc.
  • Indatuximab Ravtansine/BT-062 - Biotest
  • Anti-PSMA ADC Therapeutic - Progenics Pharmaceuticals
  • Polatuzumab Vedotin/RG7596 - Roche Genentech
  • Pinatuzumab Vedotin/RG7593 - Roche Genentech
  • Lifastuzumab Vedotin/RG7599 - Roche Genentech
  • Anti-guanylyl Cyclase C/Anti-GCC ADC - Takeda Millennium
  • Inotuzumab Ozogamicin (CMC-544) - Pfizer

第8章 動向および発展

  • ADCは最先端の悪性血液疾患治療薬
  • 乳癌患者に希望をもたらすADC

第9章 ADC業界における戦略的な事業提携

第10章 競争環境

  • Seattle Genetics
  • Roche
  • Immunogen, Inc.
  • Bayer Healthcare
  • Novartis
  • Immunomedics
  • Agensys, Inc.

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Antibody drug conjugates are the new age therapeutic agents. These are examples of immunoconjugates and bioconjugates. They combine the unique targeting property of monoclonal antibodies and the cancer cell killing ability of cytotoxic drugs. This concept of a "magic bullet" to deliver cytotoxic therapy to the site of a tumor has been envisioned for a century. But its success has become possible only now with the recent technological advancements. The recent approvals of ADCETRIS and Kadcyla followed by various Antibody Drug Conjugates (ADCs) in pipeline highlight the potential for new therapeutic innovations in the ADC industry.

According to this edition of the report "Global Antibody Drug Conjugate Market Outlook 2020", the ADC market is anticipated to reach around US$ 12.7 Billion by 2020. In our report, there is a detailed analysis of the market for ADCETRIS and Kadcyla. An estimation of the market potential of these drugs has been done keeping in mind that these drugs are being tested in clinical trials for various indications, apart from the ones which are already approved. The mentioned ADCs will take some time to show their complete market potential, we believe.

Moreover, in our report we have provided information about the ADCs at various stages of clinical development. We have highlighted the various cancer indications that these ADCs target and the cytotoxic drugs that are commonly used for their development. Apart from this, the study provides comprehensive analysis of various ADCs in advanced stages of development. In addition, the report highlights the major drivers and challenges, latest trends and developments and strategic collaborations impacting the industry's growth.

The latter part of the report discusses some of the prominent players in the ADC market. A brief business overview of each player has been provided along with their product and pipeline portfolios and recent developments. Moreover, comparative analyses of their strengths and weaknesses have also been done. Overall, the report will prove as a complete source of knowledge and analysis for clients and potential investors.

Table of Contents

1. Analyst View

2. Research Methodology

3. Antibody Drug Conjugate (ADC) - An Introduction

4. ADC Market Outlook to 2020

  • 4.1 ADCETRIS
    • 4.1.1 Market Potential
    • 4.1.2 Market Size and Forecasts to 2020
  • 4.2 Kadcyla
    • 4.2.1 Market Potential
    • 4.2.2 Market Size and Forecasts to 2020

5. ADC Pipeline Analysis

  • 5.1 By Phase
  • 5.2 By Indication
  • 5.3 By Drug

6. Drivers and Challenges

  • 6.1 Drivers
    • 6.1.1 Advances in Linking Technologies Re-Instills Hope in ADC
    • 6.1.2 Efforts towards Patent Protection to Drive ADC Market
  • 6.2 Challenges
    • 6.2.1 Production Hurdles and Cost
    • 6.2.2 Inadequacy of Experienced Manufacturers
    • 6.2.3 Regulatory Challenges

7. Current Status of Potential ADCs in Pipeline

  • 7.1 Glembatumumab Vedotin Therapeutics /CDX-011 - Celldex
  • 7.2 Coltuximab Ravtansine/SAR3419 - Immunogen Inc.
  • 7.3 Indatuximab Ravtansine/BT-062 - Biotest
  • 7.4 Anti-PSMA ADC Therapeutic - Progenics Pharmaceuticals
  • 7.5 Polatuzumab Vedotin/RG7596 - Roche Genentech
  • 7.6 Pinatuzumab Vedotin/RG7593 - Roche Genentech
  • 7.7 Lifastuzumab Vedotin/RG7599 - Roche Genentech
  • 7.8 Anti-guanylyl Cyclase C/Anti-GCC ADC - Takeda Millennium
  • 7.9 Inotuzumab Ozogamicin (CMC-544) - Pfizer

8. Trends and Developments

  • 8.1 ADC at the Forefront to Treat Hematological Malignancies
  • 8.2 ADCs Providing Advantages to Breast Cancer Patients

9. Strategic Collaborations in the ADC Industry

10. Competitive Assessment

  • 10.1 Seattle Genetics
  • 10.2 Roche
  • 10.3 Immunogen, Inc.
  • 10.4 Bayer Healthcare
  • 10.5 Novartis
  • 10.6 Immunomedics
  • 10.7 Agensys, Inc

List of Figures:

  • Figure 3-1: ADC - Mechanism of Action
  • Figure 4-1: Global - ADC Market (Billion US$), 2014-2020
  • Figure 4-2: Global - ADCETRIS Market (Million US$), 2011-2013
  • Figure 4-3: Global - ADCETRIS Market (Billion US$), 2014-2020
  • Figure 4-4: Global - Kadcyla Market (Billion US$), 2014-2020
  • Figure 5-1: Pipeline ADCs by Clinical Phase (2014)
  • Figure 5-2: Pipeline ADCs by Indication (2014)
  • Figure 5-3: Pipeline ADCs by Drug (2014)

List of Tables:

  • Table 4-1: Potential Patients for ADCETRIS (2012)
  • Table 4-2: Ongoing Trials for ADCETRIS
  • Table 4-3: Potential Patients for Kadcyla (2012)
  • Table 4-4: Ongoing Trials for Kadcyla
  • Table 7-1: ADCs in Pipeline
  • Table 9-1: Strategic Collaborations in ADC Industry
  • Table 10-1: Top Companies by ADCs in Pipeline (2014)
  • Table 10-2: Seattle Genetics - ADCs in Pipeline
  • Table 10-3: Seattle Genetics - ADCs Collaborator Pipeline
  • Table 10-4: Seattle Genetics - Strengths and Weaknesses
  • Table 10-5: Roche - ADC Collaborator Pipeline
  • Table 10-6: Roche - Strengths and Weaknesses
  • Table 10-7: Immunogen, Inc. - ADCs in Pipeline
  • Table 10-8: Immunogen, Inc. - ADC Collaborator Pipeline
  • Table 10-9: Immunogen, Inc. - Strengths and Weaknesses
  • Table 10-10: Bayer Healthcare - ADCs in Pipeline
  • Table 10-11: Bayer Healthcare - Strengths and Weaknesses
  • Table 10-12: Novartis Pharmaceuticals - ADCs in Pipeline
  • Table 10-13: Novartis Pharmaceuticals - Strengths and Weaknesses
  • Table 10-14: Immunomedics - ADCs in Pipeline
  • Table 10-15: Immunomedics - Strengths and Weaknesses
  • Table 10-16: Agensys, Inc. - ADC Collaborator Pipeline
  • Table 10-17: Agensys, Inc. - Strengths and Weaknesses
Back to Top